A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2018
At a glance
- Drugs MK 8504 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 11 Jul 2018 Status changed from active, no longer recruiting to completed.
- 15 May 2018 Status changed from recruiting to active, no longer recruiting.
- 08 May 2018 Planned End Date changed from 29 Jun 2018 to 15 Mar 2019.